مرافق إنتاج اللقاحات
Influenza virus vaccine for human immunisation purposes
Vaccines contrate production (bulk) against diphtheria, tetanus, rabies, tick-borne encephalitis, mumps are produced in Marburg.
These products are formulated in Marburg. Final vaccines formulation and filling is performed at another GSK site.
Vaccines contrate (bulk) for Meningococcus meningitis serumgroup A is formulated and lyophilised in Marburg.
Final packaging with formulated serumgroups C, W, Y is performed at another GSK site.
Live Smallpox vaccines, Following Investigational Medicinal Products - live recombinant HIV vaccines, live recombinant Malaria vaccines, live recombinant and inactivated recombinant Filovirus vaccines, live recombinant Flavivirus vaccines, MERS-CoV vaccines, inactivated recombinant Lassa virus vaccines, live recombinant Rift Valley Fever Virus vaccines
Clinical trial material only, no own licenses for marketing: Tuberculosis vaccine (recombinant and non-recombinant), Smallpox vaccine (recombinant), Ebola vaccine (recombinant), Bordetella vaccine, HIV vaccine (recombinant), Zika vaccine (recombinant), Typhus vaccine, RSV, Newcastle Disease Virus (Drug Substance, recombinant), Influenza A (PR8 vaccine).
Clinical trial material only, no own licenses for marketing; develops and produces RNA vaccines encoding Rabies antigens.
Clinical trial material only, no own licenses for marketing: produces self-amplifying RNA vaccines encoding Ebola, Marburg or Lassavirus antigens.